

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
27 May 2022 (27.05.2022)



(10) International Publication Number
WO 2022/106460 A3

(51) International Patent Classification:

A61K 39/395 (2006.01) A61P 37/00 (2006.01)
A61K 45/00 (2006.01) G01N 33/53 (2006.01)

(21) International Application Number:

PCT/EP2021/081971

(22) International Filing Date:

17 November 2021 (17.11.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/115,286 18 November 2020 (18.11.2020) US

(71) Applicant: **ASTRAZENECA AB** [SE/SE]; SE-151 85
Södertälje (SE).

(72) Inventors: **WHITE, Wendy**; MedImmune, LLC, One
MedImmune Way, Gaithersburg, Maryland 20878 (US).
GUO, Xiang; AstraZeneca Pharmaceuticals LP, 1800 Con-
cord Pike, P.O. Box 15437, Wilmington, Delaware 15437
(US).

(74) Agent: **ASTRAZENECA INTELLECTUAL PROPER-
TY**; Milstein Building Granta Park, Cambridge Cam-
bridgeshire CB21 6GH (GB).

(81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a
patent (Rule 4.17(ii))

(54) Title: STEROID SPARING

(57) Abstract: The disclosure relates to methods and compositions for the treatment of Systemic Lupus Erythematosus (SLE). Specif-
ically, the disclosure relates to methods comprising administering to a subject a type I IFN receptor inhibitor.



WO 2022/106460 A3